Surufatinib, a novel small-molecule inhibitor that targets tumour angiogenesis and immune evasion, improves progression-free survival (PFS) in patients with progressive, advanced, well-differentiated pancreatic neuroendocrine tumours (pNETs), according to results of the SANET-p trial presented at the European Society for Medical Oncology (ESMO) Virtual Congress 2020.
In patients with stage IB–IIIA EGFR-mutated (EGFRm) non-small-cell lung cancer (NSCLC) who have undergone complete tumour resection, adjuvant osimertinib significantly reduces the risk of recurrence, including in the central nervous system (CNS), results of an exploratory analysis of the phase III ADAURA trial have shown.
Delays in radical prostatectomy due to the novel coronavirus disease (COVID-19) pandemic does not result in adverse pathology, upgrading, nodal metastasis, or use of postsurgery secondary treatments, according to a recent study.
Insulin-like growth factor 1 (IGF-1) to insulin-like growth factor–binding protein 2 (IGFBP-2) ratio ≤0.85 appears to be a useful biomarker in the diagnosis of pancreatic adenocarcinoma (PDAC), suggests a recent study.
Several strategies have been proposed to help manage the adverse events (AEs) that emerged during the BEACON CRC trial which assessed the effect of encorafenib plus cetuximab in patients with BRAF V600E mutant metastatic colorectal cancer (mCRC) who had progressed after one or two prior regimens.
Hypofractionated radiotherapy (HFRT) followed by HF tumour bed-boost may have similar tumour control without an increase in toxicities compared with conventional fractionated radiotherapy (CFRT) in patients with breast cancer after breast-conserving surgery (BCS), results of a multicentre, randomized, controlled trial have shown.
The use of granulocyte colony-stimulating factors (GCSFs) as primary prophylaxis (PP) reduces the incidence of febrile neutropenia (FN) and associated hospitalization among breast cancer patients receiving docetaxel-containing chemotherapy, with 4–5 days of PP offering similar efficacy and greater healthcare expenditure savings vs 7-day PP, results of a retrospective cohort study in Hong Kong have shown.
Pembrolizumab in combination with chemotherapy significantly improves overall survival (OS), progression-free survival (PFS) and objective response rate (ORR) vs chemotherapy alone in patients with previously untreated, locally advanced unresectable or metastatic oesophageal cancer, according to results of the phase III KEYNOTE-590 study presented at the European Society for Medical Oncology (ESMO) Virtual Congress 2020.
Serum assessment of drug level may detect early nonadherence to adjuvant tamoxifen therapy and identify patients with early breast cancer at risk of poorer outcomes, new data from the CANTO study have shown.
Drawing from experience as a key investigator in landmark
clinical trials (including PALOMA, MONALEESA and
MONARCH), and his clinical experience with
CDK4/6 inhibitors, Dr Rafael Villanueva Vázquez shares his
insights into the current evidence of using CDK4/6 inhibitors
to treat HR+/HER2- ABC.